The Turnbull Government is working to cement Australia’s position as a global leader in tropical health.
Today in Cairns we announced a series of grants to commercialise medical research in the fight against tropical diseases.
Eleven organisations have been offered close to $7 million under the Coalition’s Tropical Medicine Commercialisation programme (ATMC).
The funding will help develop products that will eradicate or manage many of the diseases specific to Northern Australia and the broader region.
One of those offered a grant is James Cook University. They will receive more than $1 million for commercial development of a pan-species multistage vaccine for malaria.
Tropical diseases and health issues have an enormous impact on quality of life and economic development, so there’s a huge opportunity for Australian medical research to play a key role in solving these problems. This is why the Turnbull Government is delivering this vital funding to bridge the gap between invention and commercialisation of Australian ideas.
This investment is part of a broader Coalition strategy to build Australia’s primary research capacity and support the development of Northern Australia.
The successful applicants reflect Australia’s particular strength in tropical medicine and represent a wide range of research fields, including malaria, hepatitis C, tuberculosis and leishmaniasis.
The organisations offered ATMC funding are:
- Glaxosmithkline Consumer Healthcare Australia
- Medicines Development
- Telethon Kids Institute
- Griffith University
- Atomo Diagnostics
- Murdoch Children's Research Institute
- James Cook University
- Epichem
- The University of Queensland
- Burnet Institute
- Designmedix
